Timing the Stem Cell Opportunity
Executive Summary
Companies are drawing parallels between the monoclonal antibody industry and stem cells, and they are trying to strike a balance between gaining a stake in a field with tremendous potential without being too early. Stem cells have the potential to treat some of the largest degenerative diseases in the cardiovascular, neurological, orthopedic segments--markets worth in the double digit billions, according to a recent report on Tissue Engineering, issued by Medtech Insight. No company wants to be left behind.
You may also be interested in...
Multiple Paths of Convergence in Tissue Engineering
A collaboration within Carnegie Mellon is using ink-jet printing technology to create spatial patterns of growth factors, and in turn using them to influence the development of stem cells in vitro. The technology could provide a better means of harnessing the power of growth factor biology in regenerative medicine. The team is also using it to begin to develop rudimentary artificial bone-tendon-muscle constructs for eventual clinical use.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.